期刊
ANNALS OF NEUROLOGY
卷 68, 期 4, 页码 540-545出版社
WILEY
DOI: 10.1002/ana.22065
关键词
-
资金
- Canadian Institutes of Heath Research
- Multiple Sclerosis Society of Canada Research Foundation
- Ohio Department of Development (Center for Stem Cell and Regenerative Medicine)
- Hematopoietic Stem Cell Core Facility of the Case Comprehensive Cancer Center (NCI) [P30 CA43703]
- McGill William Dawson Chair
- MNI Killam awards
- Multiple Sclerosis Society of Canada
Human mesenchymal stem cells (hMSCs) are being considered for clinical trials of multiple sclerosis (MS). We examined the effects of adult bone marrow-derived hMSCs on responses of primary human Th1, Th17, and Th1/17 double-expressing T-cell subsets, all implicated in MS. As expected, soluble products from hMSCs inhibited Th1 responses; however, Th17 responses were increased. Secretion of interleukin (IL)-10, considered anti-inflammatory, was decreased. Pretreating hMSCs with the proinflammatory cytokine IL-1 beta accentuated these effects, and caused decreases in the Th1/17 subset. These findings underscore the importance of further preclinical work and immune-monitoring to define hMSC effects on disease-relevant immune responses under variable conditions. ANN NEUROL 2010;68:540-545
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据